Drug Giant Pfizer to Build $100 Million R&D Center in Boston
06/13/2011
The new world headquarters for the Centers for Therapeutic Innovation will house 40 employees and Pfizer's drug-development activity, and complement the company's existing offices in Cambridge.
Work at the facility will be done in collaboration with various renowned Boston-based medical and research centers. They include: the University of Massachusetts Medical School, Tufts Medical School, Beth Israel Deaconess Medical Center, Children's Hospital Boston, Partners Healthcare, Harvard University, Boston University and Tufts University. Pfizer indicated in a press release these partners could earn "milestone payments" for successful development of the "next generation of medicines."
"These partnerships allow leading medical and clinical experts to join with Pfizer's highly-skilled scientists and advanced drug development capabilities to speed the translation of innovative science into medicines for patients," said Jose Carlos Gutierrez-Ramos, Ph.D., senior VP and head of BioTherapeutics Research and Development for Pfizer. "Our ultimate goal is to bridge the gap between scientific discovery and the delivery of promising candidates to the pipeline."
Project Announcements
American Industrial Group Expands Posey County, Indiana, Manufacturing Operations
01/06/2026
Eurofins Lancaster Laboratories Expands Lancaster County, Pennsylvania, Research Operations
01/03/2026
Creative 3D Technologies Expands Cedar Park, Texas, Headquarters-Manufacturing Operations
01/03/2026
Valerie Health Plans Chattanooga, Tennessee, Operations
01/02/2026
Samsung Biologics Plans Rockville, Maryland, Manufacturing Operations
12/31/2025
Kraken Technologies Limited Plans New York City Headquarters Operations
12/29/2025
Most Read
-
The Workforce Bottleneck in America’s Manufacturing Revival
Q4 2025
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
Data Centers in 2025: When Power Became the Gatekeeper
Q4 2025
-
Tariff Shockwaves Hit the Industrial Sector
Q4 2025
-
Investors Seek Shelter in Food-Focused Real Estate
Q3 2025
-
The Permit Puzzle and the Path to Groundbreaking
Q3 2025
-
Supply Chain Whiplash Reshapes CRE
Q3 2025